Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker ATOS
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 10, 2026 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 9, 2026 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 9, 2026 | ATOS Atossa Therapeutics, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Oct 9, 2026 | ATOS Atossa Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Sep 29, 2026 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 18, 2026 | ATOS Atossa Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 7, 2026 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 11, 2026 | ATOS Atossa Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 8, 2026 | ATOS Atossa Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 16, 2026 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Feb 20, 2026 | ATOS Atossa Therapeutics, Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 20, 2026 | ATOS Atossa Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 17, 2026 | ATOS Atossa Therapeutics, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Feb 11, 2026 | ATOS Atossa Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 26, 2026 | ATOS Atossa Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jan 26, 2026 | ATOS Atossa Therapeutics, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Jan 26, 2026 | ATOS Atossa Therapeutics, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Jan 9, 2026 | ATOS Atossa Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 9, 2026 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 6, 2026 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Dec 4, 2025 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 12, 2025 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 14, 2025 | ATOS Atossa Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 14, 2025 | ATOS Atossa Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Sep 26, 2025 | ATOS Atossa Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Sep 8, 2025 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 21, 2025 | ATOS Atossa Therapeutics, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Aug 12, 2025 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 13, 2025 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 12, 2025 | ATOS Atossa Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 7, 2025 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Mar 25, 2025 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 12, 2025 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Feb 24, 2025 | ATOS Atossa Therapeutics, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Feb 4, 2025 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Dec 10, 2024 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 19, 2024 | ATOS Atossa Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 12, 2024 | ATOS Atossa Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 4, 2024 | ATOS Atossa Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
39 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:38 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances